The Life Sciences Report

Resverlogix Corp. TICKER: RVX:TSX Resverlogix Corp. is a clinical-stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus.

The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

The Life Sciences Report Interview with George Zavoico (3/7/13) "Resverlogix Corp. has almost doubled from six months ago, and we're seeing some consolidation at this time as we await results from the randomized, double-blinded phase 2b ASSURE trial of the company's lead drug candidate, RVX-208, for coronary artery disease. Top-line results are expected in May or June. If the results show a significant decrease in atherosclerotic plaque volume in the coronary arteries, as measured by intravascular ultrasound imaging (IVUS), and an increase in high-density lipoprotein (HDL) levels, it will be a huge win for the company.

Positive results would also help validate Resverlogix's drug discovery platform. RVX-208 is inhibitor of bromodomain and extra-terminal (BET) proteins involved in gene transcription. By this mechanism of action, RVX-208 increases the production of apolipoprotein A-1 (ApoA-1), making new HDL particles to remove cholesterol from plaques via reverse cholesterol transport. Resverlogix has identified other bromodomain inhibitors that could be useful in treating some cancers, autoimmune and neurodegenerative diseases, and diabetes. . .If all of that goes very smoothly, it's possible that the company might get a phase 3 trial going by the end of the year. To be on the conservative side, early 2014 is a safer projection." More >

The Life Sciences Report Interview with Jim Letourneau (1/17/13) "Resverlogix Corp. is developing RVX-208 as a first-in-class small molecule inhibitor of BET bromodomains for the clinical reversal of atherosclerosis. . .currently, RVX-208 is being evaluated in phase 2 clinical trials. The therapy acts by stimulating gene transcription of ApoA-1 via an epigenetic mechanism. ApoA-1 has been documented to trigger atherosclerotic plaque regression by increasing functional high-density lipoproteins. The clinical trials are monitored using ultrasound to measure changes arterial diameter and arterial wall thickness. That's the main story that got me interested in this company. The exciting thing is that these BET inhibitors are relevant to cancer and diabetes, in addition to cardiovascular disease. This is a hot field. . . Resverlogix is busily patenting its science to build an intellectual property fence around the proteins it has been working on." More >

George Zavoico, MLV & Co (10/15/12) "Resverlogix Corp. announced commencement of a phase 2 exploratory trial of its lead drug candidate, RVX-208, in patients with pre-diabetes mellitus. . .the 20-patient trial will investigate whether RVX-208 affects insulin dynamics such as secretion and signal sensitivity. . .the investigational trial announced today marks Resverlogix's first foray into additional clinical settings for RVX-208, which is currently in a Phase IIb trial investigating the drug's capacity to reduce arterial plaque. . .while this trial may be small, it signals a commitment from Resverlogix to maximize the potential clinical impact of RVX-208. MLV is reiterating its Buy recommendation and one-year price target of CA$6.50 for Resverlogix."

The Life Sciences Report Interview with George Zavoico (9/13/12) "There is a very large potential market in the cholesterol-modulating space. . .Resverlogix Corp. has a product with a unique mechanism of action that makes it stand out. And with notable failures in the high density lipoprotein (HDL)-raising space, RVX-208 is beginning to attract attention, especially with recent news showing that its phase 2b SUSTAIN trial of RVX-208 significantly increased levels of HDL-C and Apo A-1. . .While reductions in major adverse cardiac events (MACEs) are typically the key primary endpoint the FDA likes to see, others can serve as surrogate endpoints and this translates into smaller, more cost-effective, signal-seeking trials. Resverlogix chose plaque regression, measured by intravascular ultrasound (IVUS), as its primary endpoint in another signal-seeking trial, called ASSURE. This endpoint could also serve to validate its mechanism of action. We think this validated endpoint would be evident before many MACE events would occur." More >

George Zavoico, MLV & Co (8/29/12) "Yesterday morning, Resverlogix Corp. announced positive top-line results for its SUSTAIN phase 2b trial of 176 patients with cardiovascular disease. . .we believe this week's data are the first clear indication that RVX-208 has a potent effect on lipid dynamics in patients with low-serum, high-density lipoprotein-cholesterol/ MLV is reiterating its Buy rating."

Resverlogix Corp. Content

A Message From RVX CEO Donald McCaffrey

RVX: Epigenetics Animation

Drug Therapies Explained

Resverlogix in the Media Q3/12

• Read the Resverlogix IR Blog

Back to Top

Would you like additional information on Biotechnology/Pharmaceuticals companies?

YES

disable